All In Biotech

Drug Trial Radar · NCT00553787

Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions

A Phase III Randomized, Double-Blind, Placebo Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions

Last checked: Nov 19, 2026Latest source record: Sep 10, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,487 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,487

Actual

Start

Nov 2007

Primary completion

Jun 2009

Study completion Jun 2009

Sponsor

Lead sponsor
VIVUS LLCIndustry
Sponsor type
Industry
Collaborators
Medpace, Inc.
First posted
Nov 6, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of VI0521 compared to placebo in treatment of obesity in an adult population with obesity related co-morbid conditions.

Conditions

  • Obesity
  • Type 2 Diabetes

Interventions

  • VI-0521Drug

    phentermine 15 mg and topiramate 92 mg, po once daily

  • VI-0521Drug

    phentermine 7.5 mg and topiramate 46 mg, po once daily

  • VI-0521Drug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Weight Loss From Baseline to Week 56Time frame: Baseline to 56 weeks
  2. Percentage of Subjects With a Weight Loss of at Least 5% at Week 56 With LOCFTime frame: Baseline to 56 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Ridgefield, Connecticut

  • Research Site

    New York, New York

  • Research Site

    Durham, North Carolina

  • Research Site

    Toledo, Ohio

  • Research Site

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.